Insider Transactions in Q2 2023 at Hca Healthcare, Inc. (HCA)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 12
2023
|
Richard A Hammett Group President |
SELL
Bona fide gift
|
Direct |
1,100
-7.4%
|
-
|
|
May 04
2023
|
Samuel N Hazen CEO |
BUY
Bona fide gift
|
Indirect |
12,511
+50.0%
|
-
|
|
May 04
2023
|
Samuel N Hazen CEO |
SELL
Bona fide gift
|
Direct |
12,511
-3.89%
|
-
|
|
May 01
2023
|
Erol R Akdamar Group President |
BUY
Bona fide gift
|
Indirect |
42,484
+50.0%
|
-
|
|
May 01
2023
|
Erol R Akdamar Group President |
SELL
Bona fide gift
|
Direct |
42,484
-100.0%
|
-
|
|
Apr 28
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
12,556
-30.37%
|
$3,565,904
$284.44 P/Share
|
|
Apr 28
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,123
-19.7%
|
$1,757,301
$287.33 P/Share
|
|
Apr 28
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
BUY
Exercise of conversion of derivative security
|
Direct |
8,844
+13.18%
|
$1,255,848
$142.15 P/Share
|
|
Apr 28
2023
|
Erol R Akdamar Group President |
SELL
Open market or private sale
|
Direct |
3,500
-7.61%
|
$997,500
$285.0 P/Share
|
|
Apr 24
2023
|
Hugh F Johnston Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+24.62%
|
-
|
|
Apr 24
2023
|
Michael W Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,187
+11.23%
|
-
|
|
Apr 24
2023
|
Wayne Joseph Riley Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+4.76%
|
-
|
|
Apr 24
2023
|
Andrea B Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+18.6%
|
-
|
|
Apr 24
2023
|
William R Frist Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+8.73%
|
-
|
|
Apr 24
2023
|
Thomas F Frist Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,396
+10.26%
|
-
|
|
Apr 24
2023
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
4,473
-16.74%
|
$1,288,224
$288.38 P/Share
|
|
Apr 24
2023
|
Meg Crofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+10.39%
|
-
|
|
Apr 24
2023
|
Robert J Dennis Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+4.08%
|
-
|
|
Apr 24
2023
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
663
+3.19%
|
-
|
|
Apr 24
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,464
-32.01%
|
$5,566,704
$286.25 P/Share
|
|
Apr 24
2023
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,020
+34.5%
|
$3,234,020
$101.16 P/Share
|
|
Apr 14
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
2,687
-9.83%
|
$738,925
$275.0 P/Share
|
|
Apr 12
2023
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,653
-11.79%
|
$993,616
$272.38 P/Share
|
|
Apr 12
2023
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,340
+16.99%
|
$513,540
$81.96 P/Share
|
|
Apr 10
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
2,539
-9.34%
|
$685,530
$270.0 P/Share
|
|
Apr 05
2023
|
P. Martin Paslick SVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,461
-11.29%
|
$937,931
$271.31 P/Share
|
|
Apr 05
2023
|
P. Martin Paslick SVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+16.37%
|
$486,000
$81.96 P/Share
|
|
Apr 04
2023
|
P. Martin Paslick SVP and CIO |
SELL
Open market or private sale
|
Direct |
3,034
-10.96%
|
$804,010
$265.0 P/Share
|